“Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis”. 2017. SKIN The Journal of Cutaneous Medicine 1 (3.1): s12. https://doi.org/10.25251/skin.1.supp.11.